The China Radioligand Therapy (RLT) Market was valued at $0 Million in 2025 and projected to reach to $23.9 Million by 2030, representing a compound annual growth rate of . China's radioligand therapy market stands at an inflection point, transitioning from early adoption to mainstream clinical practice.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China's RLT market is in its nascent phase with a valuation of $0.0 million in 2025, representing significant untapped potential as regulatory frameworks and clinical adoption accelerate across the country.
China's market is projected to reach $23.9 million by 2030, demonstrating a remarkable expansion driven by increasing cancer prevalence, government healthcare investments, and growing adoption of precision medicine therapies.
China's NMPA has begun approving radioligand therapies, with enhanced pathways for innovative oncology treatments accelerating market entry and clinical implementation across major healthcare institutions.
Significant government funding for nuclear medicine centers and radiopharmaceutical manufacturing capabilities in China is establishing the foundational infrastructure necessary for RLT market expansion.
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | [LU-177]-PNT2002 (Product) |
| Forecast Period | 2025-2030 |
| Growth Rate | CAGR of 13.2% from 2025 to 2030 |
| Largest Segment | PROSTATE CANCER (Indication) |
| Market Size Base Year (Billions) | ~USD 3.16 (2025) |
| Revenue Forecast (Billions) | ~USD 5.87 (2030) |
| Segments Covered | Product, Target, Indication, End User |
4 segment dimensions are covered across the global market.
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2035 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|
| OTHER END USERS | 3.19 | 1.81 | 1.74 | 9.52 | 13.68 | 17.06 | 61.44 | 42.8 |
| SPECIALIZED NUCLEAR MEDICINE CENTERS | 4.29 | 2.45 | 2.37 | 13 | 18.77 | 23.51 | 87.26 | 43.4 |
| TERTIARY CARE ACADEMIC/ COMPREHENSIVE CANCER CENTERS | 9.84 | 5.49 | 5.19 | 27.86 | 39.33 | 48.2 | 153.48 | 40.3 |
| TOTAL | 17.32 | 9.76 | 9.31 | 50.38 | 71.78 | 88.77 | 302.18 | 41.6 |
China's RLT market is projected to reach $23.9 million by 2030, up from $0.0 million in 2025, reflecting rapid market development and adoption of this precision oncology approach.
Key growth drivers in China include increasing cancer prevalence, government investments in nuclear medicine infrastructure, regulatory approvals for advanced therapies, and rising healthcare expenditure supporting precision oncology adoption.
China's RLT market is primarily driven by adoption in neuroendocrine tumors and prostate cancer, where radioligand therapies offer targeted treatment options aligned with China's precision medicine strategy.
While China's RLT market is emerging with a projected 2030 size of $23.9 million, the global market is significantly larger at $10.91 billion, indicating substantial growth potential as China expands market penetration.
China's regulatory framework is evolving to facilitate radioligand therapy approvals and clinical adoption, supported by government initiatives promoting innovation in medical technology and precision oncology treatments.
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global radioligand therapy market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the radioligand therapy market. The secondary sources used for this study include World Health Organization (WHO), National Institutes of Health (NIH), National Cancer Institute (NCI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), and Centers for Drug Evaluation and Research (CDER), International Society for Pharmaceutical Engineering (ISPE), Innovative Medicines Initiative (IMI), Society of Nuclear Medicine and Molecular Imaging (SNMMI), European Association of Nuclear Medicine (EANM), PubMed, National Center for Biotechnology Information (NCBI), International Trade Centre (ITC), Press Releases, Company Websites, and Magazines & Proprietary Databases. Secondary sources include corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; trade, business, and professional associations; and MarketsandMarkets Analysis.
A comprehensive primary research was undertaken following an initial assessment of the global radioligand therapy market landscape through secondary research. This involved conducting in-depth interviews with market experts from the demand side, including stakeholders from pharmaceutical and biotechnology firms, CROs, CMOs, and academic and research institutions. Additionally, interviews were held with key supply-side participants, such as C-suite and senior executives, product managers, and marketing and sales leaders from prominent manufacturers, distributors, and channel partners. The research covered six major geographical regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% of the primary interviews were conducted with supply-side participants, while 30% involved demand-side experts. Data collection methods included structured questionnaires, email correspondence, online surveys, personal interviews, and telephonic discussions to understand the market dynamics comprehensively.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Both bottom-up and top-down approaches were used to estimate and validate the total size of the radioligand therapy market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the market size from the estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Radioligand therapy (RLT) is a form of precision oncology that delivers targeted radiation to cancer cells while minimizing damage to healthy cells. Once administered, the ligand guides the radioactive payload directly to cancer cells, allowing for precise radiation delivery while minimizing damage to surrounding healthy tissues.
Full forecast, segment splits, and company analysis for all Radioligand Therapy (RLT) Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report